Abdominal Imaging

, Volume 30, Issue 3, pp 325–342

Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging

Invited update


New anticancer therapeutics that target tumor blood vessels promise improved efficacy and tolerability in humans. Early phase 1 drug trials have shown that the maximum tolerated dose may be inappropriate for more advanced clinical studies with efficacy endpoints. More advanced clinical trials have demonstrated that morphologic assessments of tumor response are of limited value for gauging the efficacy of treatment. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can serve as pharmacodynamic indicator of biological activity for antivascular cancer drugs by helping to define the biologically active dose. DCE-MRI studies may also predict the efficacy of treatment on the basis of changes observed. If DCE-MRI is to be used for the selection of antivascular drugs that advance into efficacy trials, then it will be necessary to develop standardized approaches to measurement and robust analytic approaches with clear accepted endpoints specified prospectively that have biological validity. Such developments will be essential for multicenter trials in which it will be necessary to establish effective cross-site standardization of measurements and evaluation.


Magnetic resonance imaging Antiangiogenesis drugs Tumor perfusion Tumor permeability Clinical trials phase 1 


  1. 1.
    Conway, EM, Collen, D, Carmeliet, P 2001Molecular mechanisms of blood vessel growthCardiovasc Res.49507521CrossRefPubMedGoogle Scholar
  2. 2.
    Folkman, J 1995Angiogenesis in cancer, vascular, rheumatoid and other diseaseNat Med.12731CrossRefPubMedGoogle Scholar
  3. 3.
    Kaban, K, Herbst, RS 2002Angiogenesis as a target for cancer therapyHematol Oncol Clin North Am.1611251171CrossRefPubMedGoogle Scholar
  4. 4.
    Choyke, PL, Dwyer, AJ, Knopp, MV 2003Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imagingJ Magn Reson Imaging17509520CrossRefPubMedGoogle Scholar
  5. 5.
    Parker, GJ, Tofts, PS 1999Pharmacokinetic analysis of neoplasms using contrast-enhanced dynamic magnetic resonance imagingTop Magn Reson Imaging10130142CrossRefPubMedGoogle Scholar
  6. 6.
    Padhani, AR 2002Dynamic contrast-enhanced MRI in clinical oncology: current status and future directionsJ Magn Reson Imaging16407422CrossRefPubMedGoogle Scholar
  7. 7.
    Leach MO, Brindle KM, Evelhoch JL, et al. Assessment of anti-angiogenic and anti-vascular therapeutics using magnetic resonance imaging: recommendations for appropriate methodology for clinical trials. In: Proceedings of the International Society of Magnetic Resonance in Medicine, 11th scientific meeting. Toronto, 2003:1268. Google Scholar
  8. 8.
    Folkman, J 1996New perspectives in clinical oncology from angiogenesis researchEur J Cancer32A25342539CrossRefPubMedGoogle Scholar
  9. 9.
    Rak, JW, St Croix, BD, Kerbel, RS 1995Consequences of angiogenesis for tumor progression, metastasis and cancer therapyAnticancer Drugs6318Google Scholar
  10. 10.
    Gilles, R, Zafrani, B, Guinebretiere, JM,  et al. 1995Ductal carcinoma in situ: MR imaging–histopathologic correlationRadiology196415419PubMedGoogle Scholar
  11. 11.
    Park, YN, Kim, YB, Yang, KM, Park, C 2000Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesisArch Pathol Lab Med12410611065PubMedGoogle Scholar
  12. 12.
    Gasparini, G, Toi, M, Miceli, R,  et al. 1999Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapyCancer J Sci Am5101111PubMedGoogle Scholar
  13. 13.
    Obermair, A, Kucera, E, Mayerhofer, K,  et al. 1997Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survivalInt J Cancer74455458CrossRefPubMedGoogle Scholar
  14. 14.
    Linderholm, B, Tavelin, B, Grankvist, K, Henriksson, R 1998Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinomaJ Clin Oncol.1631213128PubMedGoogle Scholar
  15. 15.
    Weidner, N 1998Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to growJ Pathol.184119122CrossRefPubMedGoogle Scholar
  16. 16.
    Neeman, M, Provenzale, JM, Dewhirst, MW 2001Magnetic resonance imaging applications in the evaluation of tumor angiogenesisSemin Radiat Oncol.117082CrossRefPubMedGoogle Scholar
  17. 17.
    Dvorak, HF, Nagy, JA, Feng, D,  et al. 1999Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesisCurr Top Microbiol Immunol23797132PubMedGoogle Scholar
  18. 18.
    Benjamin, LE, Golijanin, D, Itin, A,  et al. 1999Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawalJ Clin Invest103159165PubMedGoogle Scholar
  19. 19.
    Dewhirst, MW 1993

    Angiogenesis and blood flow in solid tumors

    Teicher, B eds. Drug resistance in oncologyMarcel DekkerNew York324
    Google Scholar
  20. 20.
    Braun, RD, Lanzen, JL, Dewhirst, MW 1999Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle in ratsAm J Physiol.277H551568PubMedGoogle Scholar
  21. 21.
    Vermeulen, PB, Gasparini, G, Fox, SB,  et al. 1996Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluationEur J Cancer32A24742484CrossRefPubMedGoogle Scholar
  22. 22.
    Kerckhaert, OA, Voest, EE 2001

    The prognostic and diagnostic value of circulating angiogenic factors in cancer patients

    Voest, EED’Amore, PA eds. Tumor angiogenesis and microcirculationMarcel DekkerNew York487500
    Google Scholar
  23. 23.
    Endrich, B, Vaupel, P 1998

    The role of microcirculation in the treatment of malignant tumors: facts and fiction

    Molls, MVaupel, P eds. Blood perfusion and microenvironment of human tumorsSpringer-VerlagBerlin1939
    Google Scholar
  24. 24.
    Bhujwalla, ZM, Artemov, D, Glockner, J 1999Tumor angiogenesis, vascularization, and contrast-enhanced magnetic resonance imagingTop Magn Reson Imaging1092103PubMedGoogle Scholar
  25. 25.
    Gillies, RJ, Bhujwalla, ZM, Evelhoch, J,  et al. 2000Applications of magnetic resonance in model systems: tumor biology and physiologyNeoplasia2139151CrossRefPubMedGoogle Scholar
  26. 26.
    Brasch, R, Turetschek, K 2000MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status reportEur J Radiol.34148155CrossRefPubMedGoogle Scholar
  27. 27.
    Brasch, RC, Li, KC, Husband, JE,  et al. 2000In vivo monitoring of tumor angiogenesis with MR imagingAcad Radiol.7812823PubMedGoogle Scholar
  28. 28.
    Weissleder, R, Mahmood, U 2001Molecular imagingRadiology219316333PubMedGoogle Scholar
  29. 29.
    Howe, FA, Robinson, SP, McIntyre, DJ,  et al. 2001Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumoursNMR Biomed.14497506CrossRefPubMedGoogle Scholar
  30. 30.
    Daldrup, HE, Shames, DM, Husseini, W,  et al. 1998Quantification of the extraction fraction for gadopentetate across breast cancer capillariesMagn Reson Med40537543PubMedGoogle Scholar
  31. 31.
    Tofts, PS, Brix, G, Buckley, DL,  et al. 1999Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbolsJ Magn Reson Imaging10223232CrossRefPubMedGoogle Scholar
  32. 32.
    Barbier, EL, Lamalle, L, Decorps, M 2001Methodology of brain perfusion imagingJ Magn Reson Imaging13496520CrossRefPubMedGoogle Scholar
  33. 33.
    Sorensen, AG, Tievsky, AL, Ostergaard, L,  et al. 1997Contrast agents in functional MR imagingJ Magn Reson Imaging74755PubMedGoogle Scholar
  34. 34.
    Simonsen, CZ, Ostergaard, L, Smith, DF,  et al. 2000Comparison of gradient- and spin-echo imaging: CBF, CBV, and MTT measurements by bolus trackingJ Magn Reson Imaging12411416CrossRefPubMedGoogle Scholar
  35. 35.
    Dennie, J, Mandeville, JB, Boxerman, JL,  et al. 1998NMR imaging of changes in vascular morphology due to tumor angiogenesisMagn Reson Med.40793799PubMedGoogle Scholar
  36. 36.
    Bruening, R, Berchtenbreiter, C, Holzknecht, N,  et al. 2000Effects of three different doses of a bolus injection of gadodiamide: assessment of regional cerebral blood volume maps in a blinded reader studyAJNR2116031610PubMedGoogle Scholar
  37. 37.
    Rosen, BR, Belliveau, JW, Buchbinder, BR,  et al. 1991Contrast agents and cerebral hemodynamicsMagn Reson Med.19285292PubMedGoogle Scholar
  38. 38.
    Wenz, F, Rempp, K, Hess, T,  et al. 1996Effect of radiation on blood volume in low-grade astrocytomas and normal brain tissue: quantification with dynamic susceptibility contrast MR imagingAJR166187193PubMedGoogle Scholar
  39. 39.
    Moseley, ME, Vexler, Z, Asgari, HS,  et al. 1991Comparison of Gd- and Dy-chelates for T2 contrast-enhanced imagingMagn Reson Med.22259264PubMedGoogle Scholar
  40. 40.
    Reimer, P, Schuierer, G, Balzer, T, Peters, PE 1995Application of a superparamagnetic iron oxide (Resovist) for MR imaging of human cerebral blood volumeMagn Reson Med.34694697PubMedGoogle Scholar
  41. 41.
    d’Arcy, JA, Collins, DJ, Rowland, IJ,  et al. 2002Applications of sliding window reconstruction with cartesian sampling for dynamic contrast enhanced MRINMR Biomed.15174183CrossRefPubMedGoogle Scholar
  42. 42.
    Knopp, EA, Cha, S, Johnson, G,  et al. 1999Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imagingRadiology211791798PubMedGoogle Scholar
  43. 43.
    Ichikawa, T, Haradome, H, Hachiya, J,  et al. 1998Characterization of hepatic lesions by perfusion-weighted MR imaging with an echoplanar sequenceAJR17010291034PubMedGoogle Scholar
  44. 44.
    Ichikawa, T, Arbab, AS, Araki, T,  et al. 1999Perfusion MR imaging with a superparamagnetic iron oxide using T2-weighted and susceptibility-sensitive echoplanar sequences: evaluation of tumor vascularity in hepatocellular carcinomaAJR173207213PubMedGoogle Scholar
  45. 45.
    Kuhl, CK, Bieling, H, Gieseke, J,  et al. 1997Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion MR imagingRadiology2028795PubMedGoogle Scholar
  46. 46.
    Kvistad, KA, Lundgren, S, Fjosne, HE,  et al. 1999Differentiating benign and malignant breast lesions with T2*-weighted first pass perfusion imagingActa Radiol404551PubMedGoogle Scholar
  47. 47.
    Weind, KL, Maier, CF, Rutt, BK, Moussa, M 1998Invasive carcinomas and fibroadenomas of the breast: comparison of microvessel distributions—implications for imaging modalitiesRadiology208477483PubMedGoogle Scholar
  48. 48.
    Yung WKA, Friedman H, Conrad C, et al. A phase I trial of single-agent PTK 787/ZK 222584 (PTK/ZK), an oral VEGFR tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme. In: American Society of Clinical Oncology. Chicago, 2003:395Google Scholar
  49. 49.
    Larsson, HB, Stubgaard, M, Frederiksen, JL,  et al. 1990Quantitation of blood-brain barrier defect by magnetic resonance imaging and gadolinium-DTPA in patients with multiple sclerosis and brain tumorsMagn Reson Med.16117131PubMedGoogle Scholar
  50. 50.
    Gowland, P, Mansfield, P, Bullock, P,  et al. 1992Dynamic studies of gadolinium uptake in brain tumors using inversion-recovery echo-planar imagingMagn Reson Med.26241258PubMedGoogle Scholar
  51. 51.
    Parker, GJ, Suckling, J, Tanner, SF,  et al. 1997Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kineticsJ Magn Reson Imaging7564574PubMedGoogle Scholar
  52. 52.
    Flickinger, FW, Allison, JD, Sherry, RM, Wright, JC 1993Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRIMagn Reson Imaging11617620CrossRefPubMedGoogle Scholar
  53. 53.
    Kaiser, WA, Zeitler, E 1989MR imaging of the breast: fast imaging sequences with and without Gd-DTPA Preliminary observationsRadiology170681686PubMedGoogle Scholar
  54. 54.
    Gribbestad, IS, Nilsen, G, Fjosne, HE,  et al. 1994Comparative signal intensity measurements in dynamic gadolinium-enhanced MR mammographyJ Magn Reson Imaging4477480PubMedGoogle Scholar
  55. 55.
    Evelhoch, JL 1999Key factors in the acquisition of contrast kinetic data for oncologyJ Magn Reson Imaging10254259CrossRefPubMedGoogle Scholar
  56. 56.
    Parker, GJ, Baustert, I, Tanner, SF, Leach, MO 2000Improving image quality and T(1) measurements using saturation recovery turboFLASH with an approximate K-space normalisation filterMagn Reson Imaging18157167CrossRefPubMedGoogle Scholar
  57. 57.
    Tofts, PS 1997Modeling tracer kinetics in dynamic Gd-DTPA MR imagingJ Magn Reson Imaging791101PubMedGoogle Scholar
  58. 58.
    Tofts, PS, Berkowitz, B, Schnall, MD 1995Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability modelMagn Reson Med.33564568PubMedGoogle Scholar
  59. 59.
    Landis, CS, Li, X, Telang, FW,  et al. 2000Determination of the MRI contrast agent concentration time course in vivo following bolus injection: effect of equilibrium transcytolemmal water exchangeMagn Reson Med.44563574CrossRefPubMedGoogle Scholar
  60. 60.
    Buckley, DL 2002Transcytolemmal water exchange and its affect on the determination of contrast agent concentration in vivoMagn Reson Med.47420421CrossRefPubMedGoogle Scholar
  61. 61.
    Weinmann, HJ, Laniado, M, Mutzel, W 1984Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteersPhysiol Chem Phys Med NMR16167172PubMedGoogle Scholar
  62. 62.
    Rijpkema, M, Kaanders, JH, Joosten, FB,  et al. 2001Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumorsJ Magn Reson Imaging14457463CrossRefPubMedGoogle Scholar
  63. 63.
    Buckley, DL 2002Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T(1)-weighted MRIMagn Reson Med.47601606CrossRefPubMedGoogle Scholar
  64. 64.
    Stomper, PC, Winston, JS, Herman, S,  et al. 1997Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesionsBreast Cancer Res Treat453946CrossRefPubMedGoogle Scholar
  65. 65.
    Hawighorst, H, Knapstein, PG, Weikel, W,  et al. 1997Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvementCancer Res.5747774786PubMedGoogle Scholar
  66. 66.
    Tynninen, O, Aronen, HJ, Ruhala, M,  et al. 1999MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferationInvest Radiol.34427434CrossRefPubMedGoogle Scholar
  67. 67.
    Buckley, DL, Drew, PJ, Mussurakis, S,  et al. 1997Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRIJ Magn Reson Imaging7461464PubMedGoogle Scholar
  68. 68.
    Hulka, CA, Edmister, WB, Smith, BL,  et al. 1997Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesisRadiology205837842PubMedGoogle Scholar
  69. 69.
    Cooper, RA, Carrington, BM, Loncaster, JA,  et al. 2000Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervixRadiother Oncol.575359CrossRefPubMedGoogle Scholar
  70. 70.
    Su, MY, Cheung, YC, Fruehauf, JP,  et al. 2003Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancerJ Magn Reson Imaging18467477CrossRefPubMedGoogle Scholar
  71. 71.
    Knopp, MV, Weiss, E, Sinn, HP,  et al. 1999Pathophysiologic basis of contrast enhancement in breast tumorsJ Magn Reson Imaging10260266CrossRefPubMedGoogle Scholar
  72. 72.
    Bhujwalla, ZM, Artemov, D, Natarajan, K,  et al. 2001Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenograftsNeoplasia3143153CrossRefPubMedGoogle Scholar
  73. 73.
    Pham, CD, Roberts, TP, Bruggen, N,  et al. 1998Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factorCancer Invest16225230PubMedGoogle Scholar
  74. 74.
    Gossmann, A, Helbich, TH, Kuriyama, N,  et al. 2002Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiformeJ Magn Reson Imaging15233240CrossRefPubMedGoogle Scholar
  75. 75.
    Thomas A, Morgan B, Drevs J, et al. Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of 2 phase 1 studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer. In: Proceedings of American Society of Clinical Oncology. San Francisco, 2001:A279Google Scholar
  76. 76.
    Matsubayashi, R, Matsuo, Y, Edakuni, G,  et al. 2000Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: correlation of MR findings with histologic features and expression of growth factorsRadiology217841848PubMedGoogle Scholar
  77. 77.
    Yamashita, Y, Baba, T, Baba, Y,  et al. 2000Dynamic contrast-enhanced MR imaging of uterine cervical cancer: pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapyRadiology216803809PubMedGoogle Scholar
  78. 78.
    Lyng, H, Vorren, AO, Sundfor, K,  et al. 2001Assessment of tumor oxygenation in human cervical carcinoma by use of dynamic Gd-DTPA–enhanced MR imagingJ Magn Reson Imaging14750756CrossRefPubMedGoogle Scholar
  79. 79.
    Konouchi, H, Asaumi, J, Yanagi, Y,  et al. 2003Evaluation of tumor proliferation using dynamic contrast enhanced-MRI of oral cavity and oropharyngeal squamous cell carcinomaOral Oncol.39290295CrossRefPubMedGoogle Scholar
  80. 80.
    Woude, HJ, Verstraete, KL, Hogendoorn, PC,  et al. 1998Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization?Radiology208821828PubMedGoogle Scholar
  81. 81.
    Liu, PF, Krestin, GP, Huch, RA,  et al. 1998MRI of the uterus, uterine cervix, and vagina: diagnostic performance of dynamic contrast-enhanced fast multiplanar gradient-echo imaging in comparison with fast spin-echo T2-weighted pulse imagingEur Radiol.814331440CrossRefPubMedGoogle Scholar
  82. 82.
    Barentsz, JO, Jager, GJ, Vierzen, PB,  et al. 1996Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imagingRadiology201185193PubMedGoogle Scholar
  83. 83.
    Jager, GJ, Ruijter, ET, Kaa, CA,  et al. 1997Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic resultsRadiology203645652PubMedGoogle Scholar
  84. 84.
    Huch Boni, RA, Boner, JA, Lutolf, UM,  et al. 1995Contrast-enhanced endorectal coil MRI in local staging of prostate carcinomaJ Comput Assist Tomogr19232237PubMedGoogle Scholar
  85. 85.
    Hawighorst, H, Weikel, W, Knapstein, PG,  et al. 1998Angiogenic activity of cervical carcinoma: assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcomeClin Cancer Res423052312PubMedGoogle Scholar
  86. 86.
    Mayr, NA, Yuh, WT, Magnotta, VA,  et al. 1996Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assayInt J Radiat Oncol Biol Phys.36623633CrossRefPubMedGoogle Scholar
  87. 87.
    Gilles, R, Guinebretiere, JM, Shapeero, LG,  et al. 1993Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patientsRadiology188473478PubMedGoogle Scholar
  88. 88.
    Kerslake, RW, Fox, JN, Carleton, PJ,  et al. 1994Dynamic contrast-enhanced and fat suppressed magnetic resonance imaging in suspected recurrent carcinoma of the breast: preliminary experienceBr J Radiol.6711581168PubMedGoogle Scholar
  89. 89.
    Mussurakis, S, Buckley, DL, Bowsley, SJ,  et al. 1995Dynamic contrast-enhanced magnetic resonance imaging of the breast combined with pharmacokinetic analysis of gadolinium-DTPA uptake in the diagnosis of local recurrence of early stage breast carcinomaInvest Radiol.30650662PubMedGoogle Scholar
  90. 90.
    Kinkel, K, Tardivon, AA, Soyer, P,  et al. 1996Dynamic contrast-enhanced subtraction versus T2-weighted spin-echo MR imaging in the follow-up of colorectal neoplasm: a prospective study of 41 patientsRadiology200453458PubMedGoogle Scholar
  91. 91.
    Hawnaur, JM, Zhu, XP, Hutchinson, CE 1998Quantitative dynamic contrast enhanced MRI of recurrent pelvic masses in patients treated for cancerBr J Radiol.7111361142PubMedGoogle Scholar
  92. 92.
    Dao, TH, Rahmouni, A, Campana, F,  et al. 1993Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imagingRadiology187751755PubMedGoogle Scholar
  93. 93.
    Heywang-Kobrunner, SH, Schlegel, A, Beck, R,  et al. 1993Contrast-enhanced MRI of the breast after limited surgery and radiation therapyJ Comput Assist Tomogr17891900PubMedGoogle Scholar
  94. 94.
    Blomqvist, L, Fransson, P, Hindmarsh, T 1998The pelvis after surgery and radio-chemotherapy for rectal cancer studied with Gd-DTPA–enhanced fast dynamic MR imagingEur Radiol8781787CrossRefPubMedGoogle Scholar
  95. 95.
    Barentsz, JO, Berger-Hartog, O, Witjes, JA,  et al. 1998Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imagingRadiology207791797PubMedGoogle Scholar
  96. 96.
    Reddick, WE, Taylor, JS, Fletcher, BD 1999Dynamic MR imaging (DEMRI) of microcirculation in bone sarcomaJ Magn Reson Imaging10277285CrossRefPubMedGoogle Scholar
  97. 97.
    Woude, HJ, Bloem, JL, Verstraete, KL,  et al. 1995Osteosarcoma and Ewing’s sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgeryAJR165593598PubMedGoogle Scholar
  98. 98.
    Knopp, MV, Brix, G, Junkermann, HJ, Sinn, HP 1994MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapyMagn Reson Imaging Clin North Am2633658Google Scholar
  99. 99.
    Padhani AR, Hayes C, Assersohn L, et al. Response of breast carcinoma to chemotherapy—MR permeability changes using histogram analysis. In: International Society for Magnetic Resonance in Medicine, 8th scientific meeting. Denver, 2000:2160Google Scholar
  100. 100.
    Devries, AF, Griebel, J, Kremser, C,  et al. 2001Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinomaCancer Res.6125132516PubMedGoogle Scholar
  101. 101.
    Vries, A, Griebel, J, Kremser, C,  et al. 2000Monitoring of tumor microcirculation during fractionated radiation therapy in patients with rectal carcinoma: preliminary results and implications for therapyRadiology217385391PubMedGoogle Scholar
  102. 102.
    Mayr, NA, Yuh, WT, Arnholt, JC,  et al. 2000Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancerJ Magn Reson Imaging1210271033CrossRefPubMedGoogle Scholar
  103. 103.
    George, ML, Dzik-Jurasz, AS, Padhani, AR,  et al. 2001Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancerBr J Surg.8816281636CrossRefPubMedGoogle Scholar
  104. 104.
    Padhani, AR, MacVicar, AD, Gapinski, CJ,  et al. 2001Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imagingRadiology218365374PubMedGoogle Scholar
  105. 105.
    Burn, PR, McCall, JM, Chinn, RJ,  et al. 2000Uterine fibroleiomyoma: MR imaging appearances before and after embolization of uterine arteriesRadiology214729734PubMedGoogle Scholar
  106. 106.
    Jha, RC, Ascher, SM, Imaoka, I, Spies, JB 2000Symptomatic fibroleiomyomata: MR imaging of the uterus before and after uterine arterial embolizationRadiology217228235PubMedGoogle Scholar
  107. 107.
    Li, W, Brophy, DP, Chen, Q,  et al. 2000Semiquantitative assessment of uterine perfusion using first pass dynamic contrast-enhanced MR imaging for patients treated with uterine fibroid embolizationJ Magn Reson Imaging1210041008CrossRefPubMedGoogle Scholar
  108. 108.
    Lankester KJ, Taylor NJ, Stirling JJ, et al. Conventional cytotoxic chemotherapy agents do not have acute antivascular effects, as measured by dynamic contrast enhanced MRI (DCE-MRI). In: Proceedings of the American Society of Clinical Oncology, 39th annual meeting. Chicago, 2003:588Google Scholar
  109. 109.
    Galbraith, SM, Maxwell, RJ, Lodge, MA,  et al. 2003Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imagingJ Clin Oncol.2128312842CrossRefPubMedGoogle Scholar
  110. 110.
    Ah-See MW, Taylor NJ, Makris A, et al. Preliminary evaluation of multi-functional MRI to predict response to neoadjuvant chemotherapy in primary breast cancer. In: Proceedings of the American Society of Clinical Oncology, 39th annual meeting. Chicago, 2003:556Google Scholar
  111. 111.
    Workman, P 2002Challenges of PK/PD measurements in modern drug developmentEur J Cancer3821892193CrossRefPubMedGoogle Scholar
  112. 112.
    Buolamwini, JK 1999Novel anticancer drug discoveryCurr Opin Chem Biol.3500509CrossRefPubMedGoogle Scholar
  113. 113.
    Morgan, B, Thomas, AL, Drevs, J,  et al. 2003Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studiesJ Clin Oncol.2139553964CrossRefPubMedGoogle Scholar
  114. 114.
    Yang, JC, Haworth, L, Sherry, RM,  et al. 2003A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancerN Engl J Med.349427434CrossRefPubMedGoogle Scholar
  115. 115.
    Vajkoczy, P, Menger, MD, Vollmar, B,  et al. 1999Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopyNeoplasia13141PubMedGoogle Scholar
  116. 116.
    Drevs, J, Muller-Driver, R, Wittig, C,  et al. 2002PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imagingCancer Res.6240154022PubMedGoogle Scholar
  117. 117.
    Jayson, GC, Zweit, J, Jackson, A,  et al. 2002Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodiesJ Natl Cancer Inst.9414841493PubMedGoogle Scholar
  118. 118.
    Galbraith, SM, Rustin, GJ, Lodge, MA,  et al. 2002Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imagingJ Clin Oncol.2038263840CrossRefPubMedGoogle Scholar
  119. 119.
    Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. In: American Society of Clinical Oncology. Chicago, 2003:3646Google Scholar
  120. 120.
    Galbraith, SM, Maxwell, RJ, Lodge, MA,  et al. 2003Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imagingJ Clin Oncol.2128312842CrossRefPubMedGoogle Scholar
  121. 121.
    Galbraith, SM, Chaplin, DJ, Lee, F,  et al. 2001Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivoAnticancer Res.2193102PubMedGoogle Scholar
  122. 122.
    Maxwell, RJ, Wilson, J, Prise, VE,  et al. 2002Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRINMR Biomed.158998CrossRefPubMedGoogle Scholar
  123. 123.
    Turetschek, K, Preda, A, Floyd, E,  et al. 2003MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer modelEur J Nucl Med Mol Imaging30448455PubMedGoogle Scholar
  124. 124.
    Checkley, D, Tessier, JJ, Kendrew, J,  et al. 2003Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumoursBr J Cancer8918891895CrossRefPubMedGoogle Scholar
  125. 125.
    O’Donell A, Trigo J, Raynaud F, et al. A phase I trial of the VEGF inhibitor SU5416, incorporating dynamic contrast enhanced MRI assessment of vascular permeability. In: 36th Annual meeting of the American Society of Clinical Oncology. New Orleans, 2000:685Google Scholar
  126. 126.
    Hoffmann, U, Brix, G, Knopp, MV,  et al. 1995Pharmacokinetic mapping of the breast: a new method for dynamic MR mammographyMagn Reson Med.33506514PubMedGoogle Scholar
  127. 127.
    Boer, JA, Hoenderop, RK, Smink, J,  et al. 1997Pharmacokinetic analysis of Gd-DTPA enhancement in dynamic three-dimensional MRI of breast lesionsJ Magn Reson Imaging7702715PubMedGoogle Scholar
  128. 128.
    Degani, H, Gusis, V, Weinstein, D,  et al. 1997Mapping pathophysiological features of breast tumors by MRI at high spatial resolutionNat Med.3780782CrossRefPubMedGoogle Scholar
  129. 129.
    Evelhoch J, Brown T, Chenevert T, et al. Consensus recommendation for acquisition of dynamic contrast-enhanced MRI data in oncology. In: Proceedings of the International Society of Magnetic Resonance in Medicine. Denver, 2000:1439Google Scholar
  130. 130.
    Brown, J, Buckley, D, Coulthard, A,  et al. 2000Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory GroupMagn Reson Imaging18765776CrossRefPubMedGoogle Scholar
  131. 131.
    Tofts, PS, Kermode, AG 1991Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental conceptsMagn Reson Med17357367PubMedGoogle Scholar
  132. 132.
    Brix, G, Semmler, W, Port, R,  et al. 1991Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imagingJ Comput Assist Tomogr15621628PubMedGoogle Scholar
  133. 133.
    Henderson, E, Rutt, BK, Lee, TY 1998Temporal sampling requirements for the tracer kinetics modeling of breast diseaseMagn Reson Imaging1610571073CrossRefPubMedGoogle Scholar
  134. 134.
    Tofts, PS, Berkowitz, BA 1994Measurement of capillary permeability from the Gd enhancement curve: a comparison of bolus and constant infusion injection methodsMagn Reson Imaging128191CrossRefPubMedGoogle Scholar
  135. 135.
    Port, RE, Knopp, MV, Hoffmann, U,  et al. 1999Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imagingJ Magn Reson Imaging10233241CrossRefPubMedGoogle Scholar
  136. 136.
    Ludemann, L, Hamm, B, Zimmer, C 2000Pharmacokinetic analysis of glioma compartments with dynamic Gd-DTPA–enhanced magnetic resonance imagingMagn Reson Imaging1812011214CrossRefPubMedGoogle Scholar
  137. 137.
    Roberts, TP 1997Physiologic measurements by contrast-enhanced MR imaging: expectations and limitationsJ Magn Reson Imaging78290PubMedGoogle Scholar
  138. 138.
    Taylor NJ, Lankester KJ, Stirling JJ, et al. Application of navigator techniques to breath-hold DCE-MRI studies of the liver. In: Proceedings of the International Society of Magnetic Resonance in Medicine, 11th scientific meeting. Toronto, 2003:1306Google Scholar
  139. 139.
    Noseworthy MD, Sussman MS, Haider M, Baruchel S. Dynamic contrast enhanced liver MRI using a motion tracking algorithm. In: Proceedings of the International Society of Magnetic Resonance in Medicine. Glasgow, Scotland, 2001:2240Google Scholar
  140. 140.
    Bland, JM, Altman, DG 1996Measurement error (a)BMJ313744PubMedGoogle Scholar
  141. 141.
    Jackson, A, Kassner, A, Zhu, XP, Li, KL 2001Reproducibility of T2* blood volume and vascular tortuosity maps in cerebral gliomasJ Magn Reson Imaging14510516CrossRefPubMedGoogle Scholar
  142. 142.
    Galbraith, SM, Lodge, MA, Taylor, NJ,  et al. 2002Reproducibility of dynamic contrast enhanced MRI in human muscle and tumours—comparison of quantitative and semi-quantitative analysisNMR Biomed.15132142CrossRefPubMedGoogle Scholar
  143. 143.
    Padhani, AR, Hayes, C, Landau, S, Leach, MO 2002Reproducibility of quantitative dynamic MRI of normal human tissuesNMR Biomed.15143154CrossRefPubMedGoogle Scholar
  144. 144.
    Evelhoch J, LoRusso P, Latif Z, et al. Reproducibility of dynamic contrast-enhanced (DCE-MRI) assessment of tumor vascularity. In: American Society of Clinical Oncology 2001 annual meeting. San Francisco, 2001:399Google Scholar
  145. 145.
    Aronen, HJ, Gazit, IE, Louis, DN,  et al. 1994Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findingsRadiology1914151PubMedGoogle Scholar
  146. 146.
    Hayes, C, Padhani, AR, Leach, MO 2002Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imagingNMR Biomed.15154163CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  1. 1.Paul Strickland Scanner Centre, Mount Vernon HospitalNorthwoodUnited Kingdom
  2. 2.Cancer Research UK Clinical Magnetic Resonance Research Group, Institute of Cancer Research and The RoyalMarsden NHS TrustSuttonUnited Kingdom

Personalised recommendations